AstraZeneca profit jumps 23% on cancer drugs, unveils $1.5bn annual savings plan
Savings drive to reinvest in drug pipeline; shares climb over 4.5%
AstraZeneca's net profit jumped 23% in the third quarter to $3.12 billion, driven by strong sales of its cancer treatments, as the British drugmaker announced a programme to save $1.5 billion a year to invest back into developing new medicines.